Smoking-Cessation and Stimulant Treatment (S-CAST)

Smoking-Cessation and Stimulant Treatment (S-CAST): Evaluation of the Impact of Concurrent Outpatient Smoking-Cessation and Stimulant Treatment on Stimulant-Dependence Outcomes

The primary objective of this study is to evaluate the impact of substance-abuse treatment as usual plus smoking-cessation treatment (TAU+SCT), relative to substance-abuse treatment as usual (TAU), on drug-abuse outcomes. Specifically, this study will evaluate whether concurrent smoking-cessation treatment improves, worsens, or has no effect on stimulant-use outcomes in smokers who are in outpatient substance-abuse treatment for cocaine or methamphetamine dependence.

Inclusion Criteria:

• Clinical diagnosis of cocaine/methamphetamine dependence
• Smoked cigarettes for at least 3 months
• Currently smoking > 6 cigarettes/day
• Have an interest in quitting smoking
• Enrolled in outpatient treatment at a participating site

Exclusion Criteria:

• Clinical diagnosis of current alcohol or sedative dependence, bipolar disorder; or a life-time diagnosis of anorexia nervosa or bulimia
• Seeking/receiving treatment for opiate-agonist replacement therapy
• Medical conditions that could compromise participant safety
• Taking medications with known/potential interactions with bupropion
• Hypersensitivity to bupropion, nicotine, or menthol
• Pregnant or breastfeeding
• Abnormal ECG
• Recent smoking cessation treatment
• Use of tobacco products other than cigarettes in the past week
• Likely to enter residential/inpatient treatment within 10 weeks
• Have all stimulant-positive urine drug screens during screening/baseline